What investment strategy does Ibionext focus on?

Ibionext focuses on VC, Growth, Buyout strategies in the private equity space.

How many portfolio companies does Ibionext have?

Ibionext has 5 active portfolio companies and 4 completed exits and 1 fund tracked on GP Intel.

Where is Ibionext headquartered?

Ibionext is headquartered in Paris, France.

What is Ibionext's assets under management?

Ibionext manages approximately €600M in assets under management.

What sectors does Ibionext invest in?

Ibionext invests across Healthcare, Software, TMT, Industrials.

Home/GPs/Ibionext

Ibionext

Paris, France·Founded 2015·

Venture Capital Growth Equity Buyout

·ibionext.com

iBionext is France's first Venture Studio dedicated to healthcare, specializing in the creation, development, and financing of innovative startups in biotech, medtech, digital health, and deep tech sectors. Founded in 2012 and based in Paris, it has co-founded and built multiple high-potential companies and raised over €600 million collectively since inception.

AUM

€600M

Funds

vintages 2018

Portfolio

Exits

SectorsHealthcare Software TMT Industrials

Key facts

HQParis, France

Founded2015

Websiteibionext.com

Recent exits

Chronolife

Healthcare2025 · 8yr hold

GrAI Matter Labs

TMT2023 · 7yr hold

GenSight Biologics

Biotech2016 · 4yr hold

Pixium Vision

MedTech2014 · 3yr hold

Coverage notes

1 fund tracked, 9 portfolio companies (5 active · 4 realized). Verified weekly from public filings and deal announcements.

Sector breakdown

9 companies

Healthcare

4 · 44%

TMT

2 · 22%

MedTech

2 · 22%

Biotech

1 · 11%

Funds & portfolio

Every fund Ibionext has raised, with its portfolio companies. Hand-checked from public filings.

1 fund

iBionext Growth FundVCharvesting

2018 · 8yr€90M5 active · 4 realized

Unrealized

5 held

Company	Sector	Geo	Entry
BrainEver	Healthcare	France	2017
Prophesee	TMT	France	2014
T-Heart	Healthcare	France	2018
Tilak Healthcare	Healthcare	France	2016
Tissium	MedTech	France	2013

BrainEverActive

Healthcare

France· Entry 2017

PropheseeActive

TMT

France· Entry 2014

T-HeartActive

Healthcare

France· Entry 2018

Tilak HealthcareActive

Healthcare

France· Entry 2016

TissiumActive

MedTech

France· Entry 2013

Realized

4 exits

Company	Sector	Geo	Entry	Exit	Type	Buyer	MOIC
Chronolife	Healthcare	France	2017	2025	Trade Sale		–
GenSight Biologics	Biotech	France	2012	2016	IPO	–	–
GrAI Matter Labs	TMT	France	2016	2023	Trade Sale		–
Pixium Vision	MedTech	France	2011	2014	IPO	–	–

ChronolifeExited 2025

Healthcare

France· Entry 2017

Trade Saleto

GenSight BiologicsExited 2016

Biotech

France· Entry 2012

IPO

GrAI Matter LabsExited 2023

TMT

France· Entry 2016

Trade Saleto

Pixium VisionExited 2014

MedTech

France· Entry 2011

IPO

Track Ibionext

Saved GPs appear in your watchlist, one click from your workspace.

About Ibionext

iBionext is France's first Venture Studio dedicated to healthcare, with €600 million of assets under management as of December 2024, founded in 2015 and headquartered in Paris. The firm specialises in the creation, development and financing of innovative startups in biotech, MedTech, digital health and deep tech sectors, combining venture capital deployment with active company-building expertise.

Investment thesis

iBionext combines venture studio operations (creating new companies internally) with traditional venture capital investments in external biotech, MedTech, digital health and deep tech startups. Investment stages span early-stage seed and Series A with selective growth-stage follow-on commitments. The venture studio model distinguishes iBionext from pure VC peers, enabling proactive company-building alongside selective external investments where market opportunities align with the platform's healthcare focus.

Recent activity

The platform tracks a single dedicated fund vehicle and 6 active portfolio companies across the venture studio and traditional VC programmes. As a venture studio with selective external investments, iBionext maintains long-duration positions aligned with the multi-year company-building cycles typical of healthcare innovation. Detailed buyer names and multiple data available on Pro at €29/month.